Validation of a decision model for preventive pharmacological strategies in postmenopausal women

European Journal of Epidemiology

Volumn 20, Issue 1, 2005, Pages 89-101

  Perreault, Sylvie ^a   Levinton, Carey ^a   Laurier, Claudine ^a   Moride, Yola ^a   Ste Marie, Louis Georges ^a   Crott, Ralph ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b EORTC DATA CENTER   (Belgium)

Author keywords

Breast cancer disease prevention; Cardiovascular ; Hip fracture ; Markov model; Postmenopausal women; Risk factors

Indexed keywords

RALOXIFENE; RECOMBINANT HORMONE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANADA; CONFIDENCE INTERVAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DATA ANALYSIS; DECISION MAKING; FEMALE; HEALTH STATISTICS; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; LIFE EXPECTANCY; LIFESPAN; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MENOPAUSAL SYNDROME; OUTCOMES RESEARCH; POPULATION RESEARCH; POSTMENOPAUSE; PREDICTION; PROBABILITY; PUBLISHING; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STANDARD; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT PLANNING; VALIDATION PROCESS;

AGED; DECISION SUPPORT TECHNIQUES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MARKOV CHAINS; MIDDLE AGED; POSTMENOPAUSE; QUEBEC; RISK FACTORS;

EID: 13444291269     PISSN: 03932990     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10654-004-9478-8     Document Type: Article

References (72)

1. Society of Obstetricians and Gynecologists of Canada Menopause Consensus Committee: National Menopause Consensus. J Soc Obstet Gynecol 1994: May 4-6.
2. Canadian Consensus Conference Menopause and Osteoporosis. Hormone replacement therapy and cardiovascular disease. J Soc Obstet Gynecol Can 1998; Chap 4.
3. Josse RG. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women. In: Prevention and management of osteoporosis: Consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. Can Med Assoc J 1996; 155: 929-934.
4. Canadian Consensus Conference Menopause and Osteoporosis. Hormone replacement therapy and cancer. J Soc Obstet Gynecol Can 1998; Chap 6.
5. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613.
6. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Eng J Med 2000; 343: 522-529.
7. Clarke S, Kelleher J, Lloyd-Jones H, et al. Transdermal hormone replacement therapy for secondary prevention of coronary heart disease in postmenopausal women. Eur Heart J 2000; 21: Suppl. 212.
8. Lenfant C. Preliminary trends in the Women's Health Initiative. Bethesda, MD: National Heart, Lung, and Blood Institute Communications of Office, April 3, 2000.
9. Manson JE, Martin KA. Postmenopausal hormone replacement therapy. N Eng J Med 2001; 345: 34-40.
10. Grady D, Herrington D, Bittner V et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002; 288: 49-57.
11. Hulley S, Furberg C, Barrett-Connor E, et al. Non-cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002; 288: 58-66.
12. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-333.
13. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifen and cardiovascular events in osteoporotic postmenopausal women. Four-year results from the multiple outcomes of raloxifen evaluation (MORE) randomized trial. JAMA 2002; 287: 847-857.
14. Lufkin EG, Wong M, Deal C. The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis. Rheum Dis Clin North Am 2001; 1: 163-185.
15. Tosteson ANA, Weinstein MC. Cost-effectiveness of hormone replacement after the menopause. Baillière's Clin Obstet Gynecol 1991; 5: 943-959.
16. Tosteson ANA, Rosenthal DI, Melton LJ, et al. Cost-effectiveness of screening perimenopausal white women for osteoporosis: Bone densitometry and hormone replacement therapy. Ann Intern Med 1990; 113: 594-603.
17. Hillner BE, Hollenberg JP, Pauker SG. Postmenopausal estrogens in prevention of osteoporosis: Benefit virtually without risk if cardiovascular effects are considered. Am J Med 1986; 80: 1115-1127.
18. Gorsky RD, Koplan JP, Peterson HB, et al. Relative risks and benefits of long term estrogen replacement therapy: A decision analysis. Obstet Gynecol 1994; 83: 161-166.
19. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980; 303: 1195-1198.
20. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,441 women without breast cancer. Lancet 1997; 350: 1047-1059.
21. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997; 277: 1140-1147.
22. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3: 419-458.
23. Sonnenberg FA, Beck J. Markov models in medical decision making: A practical guide. Med Decis Making 1993; 13: 322-338.
24. Kuntz KM, Weinstein MC. Life expectancy biases in clinical decision modeling. Med Decis Making 1995; 15: 158-169.
25. Beck JR, Pauker SG, Gottlieb JE, et al. A convenient approximation of life expectancy. Use in decision making. Am J Med 1982; 73: 889-897.
26. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy. Validation of the method. Am J Med 1982; 73: 883-888.
27. Hunink M, Glasziou P. In: Siegel J, Weeks J, Pliskin J, Elstein A, Weinstein M (eds), Decision making in health and medicine integrating evidence and values. Cambridge University Press, 2001.
28. Anderson KM, Odell DM, Wilson PWF, et al. Cardiovascular disease risk profiles. Am Heart J 1990; 121: 293-298.
29. Anderson KM, Wilson PWF, Odell PM, et al. An updated coronary profile. A statement for health professionals. Circulation 1991; 83: 356-362.
30. Grover SA, Abrahamowick M, Joseph L, et al. The benefits of treating hyperlipidemia to prevent coronary heart disease. Estimating changes in life expectancy and morbidity. JAMA 1992; 267: 816-822.
31. Daveluy C, Chénard C, Levasseur L, et al. Santé Québec et votre coeur ça va. Rapport de l'enquête québéçoise sur la santé cardiovasculaire 1990. Santé Québec 1994.
32. Pilote L, Lavoie F, Ho V, et al. Changes in the treatment and outcomes of acute myocardial infarction in Quebec, 1988-1995. Can Med Assoc J 2000; 163: 31-36.
33. Matchur DB. The stroke prevention policy model linking evidence and clinical decision. Ann Intern Med 1997; 127: 704-711.
34. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Eng J Med 1998; 339: 1349-1357.
35. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332: 767-773.
36. Levy A, Mayo NE, Grimard G. Rates of transcervical and pertrochanteric hip fractures in the province of Quebec, Canada, 1981-1992. Am J Epidemiol. 1995; 142: 428-436.
37. Santé-Québec, Enquête Générale de Santé-Québec, Rapport Préliminaire, 1992-1993.
38. Tenenhouse A, Joseph L, Kreiger, N, et al. Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: The Canadian Multicenter Osteoporosis Study (CaMos). Osteopororis Int 2000; 11: 897-904.
39. Gail MF, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879-1886.
40. Bondy ML, Lustbader ED, Halabi S, et al. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 1994; 86: 620-625.
41. Spiegelman D, Colditz GA, Hunter D, et al. Validation of the Gail et al. Model for predicting individual breast cancer. J Natl Cancer Inst. 1994; 86: 600-607.
42. Statistics Canada, Laboratory Centre for Disease Control, Health Protection Branch, Health Canada, 1995.
43. Hébert-Croteau N, Goggin P, Kishchuk N. Estimation of breast cancer risk by women aged 40 and over: A population-based study. Can J Public Health 1997; 88: 392-396.
44. Anderson FA, Brownell Wheeler H, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991; 151: 933-938.
45. Kannel WB, Wolf PA, Garrison RJ. Survival following initial cardiovascular events: 30 year follow-up. In: The Framingham Study: An epidemiological investigation of cardiovascular disease. Bethesda, MD: National Heart, Lung and Blood Institute; 1988: 35. Publication NIH 88-2969.
46. White BL, Fisher WD, Laurin CA. Rate of mortality for elderly patients after fracture of the hip in the 1980s. J Bone Joint Surg Am 1987; 69: 1335-1340.
47. Lindsay R, Meunier PJ. Osteoporosis review of the evidence for prevention, diagnosis and treatment, and cost-effectiveness analysis. Osteoporosis Int 1998; 8: S1-S88.
48. Hannan EJ, Magaziner J, Wang JJ, et al. Mortality and locomotion 6 months after hospitalization for hip fracture risk factors and risk-adjusted hospital outcomes. JAMA 2001; 285: 2736-2742.
49. Koval KJ, Zuckerman JD. Functional recovery after hip fracture. J Bone Joint Surg Am 1994; 76: 751-758.
50. Zuckerman SD. Hip fracture. N Engl J Med 1996; 334: 1519-1525.
51. Statistics Canada, Laboratory Centre for Disease Control, Health Protection Branch, Health Canada, 1996.
52. Will BP, Berthelot JM, LePetit C, et al. Estimates of the lifetimes costs of breast cancer treatment in Canada. Eur J Cancer 2000; 36: 724-735.
53. Statistics Canada, Health Division. Life Tables, Canada, and Provinces, 1990-1992. Ottawa, Ontario: Vital Statistics and Disease Registries Section; 1989. Formerly Catalog 84-537: 10
54. Chiang CL. Competing risks in mortality analysis. Annu Rev Publ Health 1991; 12: 281-307.
55. Llorca J, Delgado-Rodriguez M. Competing risks analysis using Markov chains: impact of cerebrovascular and ischaemic heart disease in cancer mortality. Int Epidemiol Assoc 2001; 30: 99-101.
56. Heart and Stroke Foundation of Canada. Heart disease and stroke in Canada. Ottawa: The Foundation: Update 2000.
57. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-1622.
58. Larosa JC, He J, Vupputuri S. Effects of statins on risk of coronary disease. A metaanalysis of randomized controlled trials. JAMA 1999; 282: 2340-2346.
59. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541.
60. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Eng J Med 2001; 344: 333-340.
61. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE Randomized Trial. JAMA 1999; 281: 2189-2197.
62. Col NF, Pauker SG, Goldberg RJ, et al. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. Arch Intern Med 1999; 159: 1458-1466.
63. Grover SA, Paquet S, Levinton C, et al. Estimating the Benefits of modifying risk factors of cardiovascular disease. Arch Intern Med 1998; 158: 655-662.
64. Fletcher S, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA 2002; 288: 366-368.
65. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet 2000; 355: 1955-1964.
66. Pahor M, Psaty BM, Aldernan MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials. Lancet 2000; 356: 1949-1954.
67. Nussbaum ES, Heros RC, Erickson DL. Cost-effectiveness of carotid endarterectomy. Neurosurgery 1996; 38: 237-244.
68. Gore JM, Granger CB, Maarten L, et al. Stroke after thrombolysis. Mortality and functional outcome in the GUSTO-I Trial. Circulation 1995; 92: 2811-2818.
69. Wong J, et al. 1990. Myocardial revascularization for chronic stable angina. Ann Intern Med 1990; 113: 852-871.
70. O'Brien BJ, et al. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. CMAJ 1994; 150: 1083-1090.
71. Health Canada. Le nouveau visage des maladies cardiovasculaires et des accidents vasculaires cérébraux au Canada. 2000. Statistics Canada.
72. Hillner BE, Philbrick JT, Becker DM. Optimal management of suspected lower-extremity deep vein thrombosis: An evaluation with cost assessment of 24 management strategies. Arch Intern Med 1992; 152: 165-175.